GWS
VIR icon

Glassman Wealth Services’s Vir Biotechnology VIR Stock Holding History

Glassman Wealth Services’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-29
Closed -$292 – 1760
2023
Q4 		$292 Sell
29
-536
-95% -$4.9K ﹤0.01% 1827
2023
Q3 		$5.29K Buy
+565
New +$8.06K ﹤0.01% 1053
2022
Q2 		– Sell
-1
Closed – – 2017
2022
Q1 		$0 Buy
+1
New +$30 ﹤0.01% 1961

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Glassman Wealth Services's VIR Position: Q1 2024 in Review

Glassman Wealth Services sold out of Vir Biotechnology (VIR) in Q1 2024, closing a stake of 29 shares — an estimated $292 sold.

Glassman Wealth Services first reported a position in VIR in Q1 2022 and held it in 3 quarters. The position peaked at $5.29K in Q3 2023. 209 funds tracked by Wall St. Rank hold VIR as of Q1 2024.

  • Glassman Wealth Services reported no remaining Vir Biotechnology position as of Q1 2024 after selling out during the quarter.
  • Glassman Wealth Services sold 29 Vir Biotechnology shares in Q1 2024, an estimated $292.
  • Glassman Wealth Services first reported a position in Vir Biotechnology in Q1 2022 and held it in 3 quarters.
  • Glassman Wealth Services's Vir Biotechnology position peaked at $5.29K in Q3 2023.
  • 209 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2024.

Based on Glassman Wealth Services's 13F filing for Q1 2024, filed 3 May 2024.